These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37034567)

  • 1. Obesity and chronic kidney disease: A current review.
    Nawaz S; Chinnadurai R; Al-Chalabi S; Evans P; Kalra PA; Syed AA; Sinha S
    Obes Sci Pract; 2023 Apr; 9(2):61-74. PubMed ID: 37034567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity Management and Chronic Kidney Disease.
    Chen Y; Dabbas W; Gangemi A; Benedetti E; Lash J; Finn PW; Perkins DL
    Semin Nephrol; 2021 Jul; 41(4):392-402. PubMed ID: 34715968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adipose tissue in chronic kidney disease development (Review).
    Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Enyedi M; Nedelea AS; Nica AE; Stefani C
    Exp Ther Med; 2021 May; 21(5):539. PubMed ID: 33815612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feeding the critically ill obese patient: a systematic review protocol.
    Secombe P; Harley S; Chapman M; Aromataris E
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):95-109. PubMed ID: 26571286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of obesity in kidney disease: recent findings and potential mechanisms.
    Kalaitzidis RG; Siamopoulos KC
    Int Urol Nephrol; 2011 Sep; 43(3):771-84. PubMed ID: 21544651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Sugar Spikes to Pressure Peaks: Navigating the World of Diabetes, Hypertension, Obesity, and Kidney Health.
    Hlyan NP; Arif T; Jaufar SS; Rehman A; Ayalew BD; Batu BJ; Hundesa MI; Hlaing MS; Islam H; Islam R; Shehryar A; Quinn M
    Cureus; 2024 Mar; 16(3):e57241. PubMed ID: 38686257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities.
    Sarzani R; Landolfo M; Di Pentima C; Ortensi B; Falcioni P; Sabbatini L; Massacesi A; Rampino I; Spannella F; Giulietti F
    Front Med (Lausanne); 2024; 11():1365183. PubMed ID: 38654832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management.
    García-Carro C; Vergara A; Bermejo S; Azancot MA; Sellarés J; Soler MJ
    Front Med (Lausanne); 2021; 8():655871. PubMed ID: 33928108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of metabolic syndrome and chronic kidney disease.
    Scurt FG; Ganz MJ; Herzog C; Bose K; Mertens PR; Chatzikyrkou C
    Obes Rev; 2024 Jan; 25(1):e13649. PubMed ID: 37783465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutrition and Obesity Impacts on Kidney Health.
    Wang AY; Kovesdy CP
    Contrib Nephrol; 2021; 199():24-42. PubMed ID: 34343991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual roles of obesity in chronic kidney disease: a review of the current literature.
    Rhee CM; Ahmadi SF; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2016 May; 25(3):208-16. PubMed ID: 26999023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity-related kidney disease: Beyond hypertension and insulin-resistance.
    Arabi T; Shafqat A; Sabbah BN; Fawzy NA; Shah H; Abdulkader H; Razak A; Sabbah AN; Arabi Z
    Front Endocrinol (Lausanne); 2022; 13():1095211. PubMed ID: 36726470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
    Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Glucose-Lowering Agents in Diabetes and CKD.
    Alicic RZ; Neumiller JJ; Galindo RJ; Tuttle KR
    Kidney Int Rep; 2022 Dec; 7(12):2589-2607. PubMed ID: 36506243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
    Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
    Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.
    Theofilis P; Vordoni A; Kalaitzidis RG
    World J Gastroenterol; 2022 Oct; 28(39):5691-5706. PubMed ID: 36338895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of obesity in chronic kidney disease: what is the best measure?
    Zoccali C; Torino C; Tripepi G; Mallamaci F
    Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):641-6. PubMed ID: 23010758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.